Publications by authors named "David Kheav"
The long-term benefits of conversion from calcineurin inhibitors (CNIs) to belatacept in kidney transplant recipients (KTr) are poorly documented A single-center retrospective work to study first-time CNI to belatacept conversion as a rescue therapy [eGFR <30 ml/min/1.73 m, chronic histological lesions, or CNI-induced thrombotic microangiopathy (TMA)]. Patient and kidney allograft survivals, eGFR, severe adverse events, donor-specific antibodies (DSA), and histological data were recorded over 36 months after conversion.
View Article and Find Full Text PDFArticle Synopsis
- People with HIV have lower success rates when getting kidney transplants compared to others, but a new medicine called belatacept might help them live longer with their new kidney.
- In a study in France, 12 patients switched from an older medicine to belatacept after getting their kidney transplant, and most of them (92%) were doing well after a year.
- The study suggests that using belatacept might be safer and better for long-term kidney health in HIV-positive patients, but more research is needed with more people to be sure.
Background: Donor-specific antibodies are associated with increased risk of antibody-mediated rejection and decreased allograft survival. Therefore, reducing the risk of these antibodies remains a clinical need in transplantation. Plasma cells are a logical target of therapy given their critical role in antibody production.
View Article and Find Full Text PDF